Change in the TCRβ repertoire, as well as CCR4 and FOXP3 expression, in PBMCs resulting from mogamulizumab or chemotherapy. (A) Change in ISDI for the TCRβ repertoire in PBMCs caused by mogamulizumab treatment of patients with (n = 16) or without (n = 8) EM and caused by chemotherapy without mogamulizumab (n = 11). Change in CCR4 (B) and FOXP3 (C) expression in PBMCs caused by mogamulizumab in patients with (n = 16) or without (n = 8) EM.